Tibet Weixinkang Medicine Co., Ltd.

Shanghai Stock Exchange 603676.SS

Tibet Weixinkang Medicine Co., Ltd. Interest Coverage Ratio for the year ending December 31, 2023: 631.84

Tibet Weixinkang Medicine Co., Ltd. Interest Coverage Ratio is 631.84 for the year ending December 31, 2023, a -34.43% change year over year. Interest coverage ratio assesses earnings' ability to cover interest expenses; higher ratios signal lower risk.

Tibet Weixinkang Medicine Co., Ltd. Interest Coverage Ratio for the year ending December 31, 2022 was 963.68, a -4.87% change year over year.
Tibet Weixinkang Medicine Co., Ltd. Interest Coverage Ratio for the year ending December 31, 2021 was 1,013.02, a 3,571.20% change year over year.
Tibet Weixinkang Medicine Co., Ltd. Interest Coverage Ratio for the year ending December 31, 2020 was 27.59.

Key data

Date	Interest Coverage Ratio	Debt to Equity Ratio	Interest Expense To Sales	Inventory Turnover Ratio

Shanghai Stock Exchange: 603676.SS

Tibet Weixinkang Medicine Co., Ltd.

CEO	Mr. Yong Zhang
IPO Date	July 21, 2017
Location	China
Headquarters	Building 4
Employees	701
Sector	Health Care
Industries Pharmaceuticals Biotechnology

Description

Tibet Weixinkang Medicine Co., Ltd. engages in the research and development, production, and sale of pharmaceutical products in China. The company's products include parenteral nutrition vitamins, electrolyte supplements, intravenous iron supplements, antibiotics, and medicine for digestive system and liver diseases. It also offers injection multivitamins, potassium magnesium aspartate for injection, iron sucrose injection, potassium aspartate injection, etc. The company was formerly known as Weixinkang Medicine Youxian Gongsi and changed its name to Tibet Weixinkang Medicine Co., Ltd. in 2015. Tibet Weixinkang Medicine Co., Ltd. was founded in 2006 and is based in Lhasa, China.

Key trends

Past 5 years